Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Publications

AR cooperates with SMAD4 to maintain skeletal muscle homeostasis.

Forouhan M. et al, (2022), Acta Neuropathol

Impact assessments of wind farms on seabird populations that overlook existing drivers of demographic change should be treated with caution

Horswill C. et al, (2022), Conservation Science and Practice, 4

Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model

Overby SJ. et al, (2022), Molecular Therapy - Nucleic Acids, 27, 1146 - 1155

Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin/utrophin double-knockout mouse model of DMD

Hanson B. et al, (2022)

PPMO-mediated exon skipping induces uniform sarcolemmal dystrophin rescue with dose-dependent restoration of circulating microRNA biomarkers and muscle biophysical properties

Chwalenia K. et al, (2022)

Control of backbone chemistry and chirality boost oligonucleotide splice switching activity.

Kandasamy P. et al, (2022), Nucleic Acids Res

Enhancing the Therapeutic Potential of Extracellular Vesicles Using Peptide Technology

Martin Perez C. et al, (2022), Methods in Molecular Biology, 2383, 119 - 141

Author Correction: GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain.

Dar GH. et al, (2021), Nat Commun, 12

Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy.

Cerro-Herreros E. et al, (2021), Mol Ther Nucleic Acids, 26, 174 - 191

GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain.

Dar GH. et al, (2021), Nat Commun, 12

Dystrophin involvement in peripheral circadian SRF signalling.

Betts CA. et al, (2021), Life Sci Alliance, 4

RASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axis.

Tognoli ML. et al, (2021), EMBO J

Amelioration of systemic inflammation via the display of two different decoy protein receptors on extracellular vesicles.

Gupta D. et al, (2021), Nat Biomed Eng, 5, 1084 - 1098

Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype by modulating AR transcriptional activity.

Lim WF. et al, (2021), Sci Adv, 7

Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy.

Meijboom KE. et al, (2021), JCI Insight, 6

Mesyl Phosphoramidate Oligonucleotides as Potential Splice Switching Agents: Impact of Backbone Structure on Activity and Intracellular Localization

HAMMOND SM. et al, (2021), Nucleic Acid Therapeutics

Extracellular vesicles as a next-generation drug delivery platform

WOOD M. et al, (2021), Nature Nanotechnology

Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases.

Aoki Y. and Wood MJA., (2021), J Neuromuscul Dis

Improving assessments of data-limited populations using life-history theory

Horswill C. et al, (2021), Journal of Applied Ecology, 58, 1225 - 1236

Mesyl Phosphoramidate Oligonucleotides as Potential Splice-Switching Agents: Impact of Backbone Structure on Activity and Intracellular Localization.

Hammond SM. et al, (2021), Nucleic Acid Ther

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?